Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 9Phase 4 6Phase 2/3 4Phase 1/2 3Phase 1 2Phase NA 1

Status

Completed 9Unknown 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Gastrointestinal 1

Conditions

Multiple Myeloma 2Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Thalidomide × Clear all
NCT04891744 2021-05-18

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Sichuan University

Phase 1/2 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

NCT02145715 2015-06-26

MUKsix

University of Leeds

Phase 1/2 Unknown
54 enrolled
Plasma cell

Multiple Myeloma

NCT00155272 2005-09-12

Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma

National Taiwan University Hospital

Phase 1/2 Unknown
19 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡